IRadimed Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US46266A1097
USD
92.50
1.29 (1.41%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
BioLife Solutions, Inc.
Artivion, Inc.
IRadimed Corp.
Silk Road Medical, Inc.
OrthoPediatrics Corp.
Treace Medical Concepts, Inc.
Atrion Corp.
Cytek Biosciences, Inc.
Varex Imaging Corp.
Nevro Corp.
Minerva Surgical, Inc.

Why is IRadimed Corp. ?

1
High Management Efficiency with a high ROE of 17.02%
2
The company is Net-Debt Free
3
Healthy long term growth as Operating profit has grown by an annual rate 94.60%
4
Flat results in Jun 26
  • ROCE(HY) Lowest at 23.52%
  • RAW MATERIAL COST(Y) Grown by 5.31% (YoY)
  • OPERATING PROFIT(Q) Lowest at USD 6.8 MM
5
With ROE of 23.76%, it has a attractive valuation with a 13.15 Price to Book Value
  • The stock is trading at a premium compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 29.71%, its profits have risen by 16.9% ; the PEG ratio of the company is 3.4
6
High Institutional Holdings at 72.54%
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
  • Their stake has increased by 4.32% over the previous quarter.
7
Market Beating performance in long term as well as near term
  • Along with generating 29.71% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to IRadimed Corp. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is IRadimed Corp. for you?

Medium Risk, High Return

Absolute
Risk Adjusted
Volatility
IRadimed Corp.
34.11%
3.55
32.28%
S&P 500
22.36%
1.63
13.19%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
21.45%
EBIT Growth (5y)
94.60%
EBIT to Interest (avg)
14.28
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.56
Sales to Capital Employed (avg)
0.86
Tax Ratio
20.79%
Dividend Payout Ratio
38.88%
Pledged Shares
0
Institutional Holding
68.22%
ROCE (avg)
58.93%
ROE (avg)
17.02%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
55
Industry P/E
Price to Book Value
13.15
EV to EBIT
45.64
EV to EBITDA
43.32
EV to Capital Employed
27.46
EV to Sales
14.24
PEG Ratio
3.36
Dividend Yield
0.88%
ROCE (Latest)
60.17%
ROE (Latest)
23.76%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company
DEBTORS TURNOVER RATIO(HY)

Highest at 7.16 times

DIVIDEND PAYOUT RATIO(Y)

Highest at 49.33%

CASH AND EQV(HY)

Highest at USD 115.45 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 1.78 times

DIVIDEND PER SHARE(HY)

Highest at USD 7.16

-8What is not working for the Company
ROCE(HY)

Lowest at 23.52%

RAW MATERIAL COST(Y)

Grown by 5.31% (YoY

OPERATING PROFIT(Q)

Lowest at USD 6.8 MM

OPERATING PROFIT MARGIN(Q)

Lowest at 33.23 %

PRE-TAX PROFIT(Q)

Lowest at USD 6.89 MM

NET PROFIT(Q)

Lowest at USD 5.22 MM

EPS(Q)

Lowest at USD 0.41

Here's what is working for IRadimed Corp.

Debtors Turnover Ratio
Highest at 7.16 times and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Cash and Eqv
Highest at USD 115.45 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Inventory Turnover Ratio
Highest at 1.78 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Dividend per share
Highest at USD 7.16
in the last five years
MOJO Watch
Company is distributing higher dividend from profits generated

DPS (USD)

Dividend Payout Ratio
Highest at 49.33%
in the last five years
MOJO Watch
Company is distributing higher proportion of profits generated as dividend

DPR (%)

Here's what is not working for IRadimed Corp.

Operating Profit
Lowest at USD 6.8 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is negative

Operating Profit (USD MM)

Operating Profit Margin
Lowest at 33.23 %
in the last five periods
MOJO Watch
Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit
Lowest at USD 6.89 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit
Lowest at USD 5.22 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is negative

Net Profit (USD MM)

EPS
Lowest at USD 0.41
in the last five periods
MOJO Watch
Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Raw Material Cost
Grown by 5.31% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales